Trial · NCT07912996
Registered outcomes21
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 21
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of Participants Experiencing Adverse Events (AEs) | Enrollment up to 92 days | |
| Primary | Percentage of Participants Experiencing Premature Study-Dug Discontinuation due to AEs | Enrollment up to 92 days | |
| Primary | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | First dose date up to 92 days | |
| Primary | Herpes Simplex Virus Type 2 (HSV-2) Shedding Rate During the Swabbing Period | Day 8 to Day 38 | |
| Secondary | Proportion of Participants Free of Genital Herpes Recurrences at Day 92 | Day 92 | |
| Secondary | Proportion of Participants Free of Genital Herpes Recurrences at Day 120 | Day 120 | |
| Secondary | Genital Herpes Lesion Rate During the Treatment Period | Up to 92 days | |
| Secondary | Genital Herpes Lesion Duration During the Treatment Period | Up to 92 days | |
| Secondary | Virologically Confirmed Genital Herpes Lesion Rate During the Treatment Period | Up to 92 days | |
| Secondary | Virologically Confirmed Genital Herpes Lesion Duration During the Treatment Period | Up to 92 days | |
| Secondary | Time to Suppression of HSV-2 Shedding | Up to 92 days | |
| Secondary | Number of HSV-2 Shedding Episodes During the Swabbing Period | Day 8 to Day 38 | |
| Secondary | Duration of HSV-2 Shedding Episodes During the Swabbing Period | Day 8 to Day 38 | |
| Secondary | Proportion of Participants With Subclinical HSV-2 Shedding During the Swabbing Period | Day 8 to Day 38 | Subclinical HSV-2 shedding is defined as swabs testing positive for HSV-2 DNA during the Swabbing Period that are not accompanied by lesions. |
| Secondary | HSV-2 DNA (Copies/mL) for Swab Samples that are Positive for HSV-2 DNA During the Swabbing Period | Day 8 to Day 38 | |
| Secondary | HSV-2 DNA (Copies/mL) for Positive Swab Samples in the Absence of Lesions (Subclinical Shedding) During the Swabbing Period | Day 8 to Day 38 | |
| Secondary | Proportion of Swab Samples With HSV-2 DNA > 4 log10 Copies/mL for Positive Swab Samples During the Swabbing Period | Day 8 to Day 38 | |
| Secondary | Proportion of Swab Samples With HSV-2 DNA > 4 log10 Copies/mL for Positive Swab Samples in the Absence of Lesions (Subclinical Shedding) During the Swabbing Period | Day 8 to Day 38 | |
| Secondary | Plasma Pharmacokinetic (PK) Parameters: Cmax of GS-1179 | Day 1 up to 92 days | Cmax is defined as the maximum observed concentration of drug at steady state. |
| Secondary | Plasma PK Parameters: AUCtau of GS-1179 | Day 1 up to 92 days | AUCtau is defined as the area under the concentration versus time curve over the dosing interval at steady state. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07912996/registered